Completed PHASE2 INTERVENTIONAL NCT00005868

Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer

Taxotere and Cisplatin as Induction Chemotherapy in Patients With Stage IIIa N2 Non Small Cell Lung Cancer (NSCLC)

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Updated 6 times since 2017 Last updated: Jul 17, 2012 Started: Mar 31, 2000 Primary completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Cancer and is currently completed. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Gravenhage (Den Haag, the Hague), Netherlands , 's-Hertogenbosch, Netherlands , Amsterdam, Netherlands , Arnhem, Netherlands , Genoa (Genova), Italy , Harderwijk, Netherlands , Heidelberg, Germany , Leiden, Netherlands , Nieuwegein, Netherlands , Nijmegen, Netherlands and 9 more locations